3,387 results match your criteria: "Hospital Juárez de México D.F.[Affiliation]"
Impact on Distance and Near Contrast Sensitivity of Multifocal Contact Lenses: A Systematic Review.
Eye Contact Lens
November 2024
Department of Optics, Pharmacology and Anatomy (K.J.M.-G., D.F., D.P.P.), University of Alicante, Alicante, Spain; and Advanced Clinic Optometry Unit (D.P.P.), Department of Ophthalmology, Medimar International Hospital, Alicante, Spain.
Purpose: To investigate the impact on distance and near contrast sensitivity (CS) after fitting multifocal contact lenses (MFCLs) for presbyopia correction according to the scientific evidence already published.
Methods: Three bibliographic search was conducted on PubMed, Web of Sciences, and Scopus. Inclusion criteria were articles written in English evaluating distance and/or near CS in presbyopic patients using MFCLs, controlled clinical trials, and articles published from 2000 to 2024.
Exploring Sex Differences in Outcomes of Dual Antiplatelet Therapy for Patients With Noncardioembolic Mild-to-Moderate Ischemic Stroke or High-Risk Transient Ischemic Attack: A Propensity-Matched Analysis of the READAPT Study Cohort.
Stroke
February 2025
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy (M.F., E.D.M., F.D.S., F. Pistoia, R.O., S.S.).
Background: Sex may impact clinical outcomes in patients with stroke treated with dual antiplatelet therapy (DAPT). We aimed to investigate the sex differences in the short-term outcomes of DAPT within a real-world population of patients with noncardioembolic mild-to-moderate ischemic stroke or high-risk transient ischemic attack.
Methods: We performed a propensity score-matched analysis from a prospective multicentric cohort study (READAPT [Real-Life Study on Short-Term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack]) by including patients with noncardioembolic mild-to-moderate stroke (National Institutes of Health Stroke Scale score of 0-10) or high-risk transient ischemic attack (age, blood pressure, clinical features, duration of transient ischemic attack, presence of diabetes [ABCD] ≥4) who initiated DAPT within 48 hours of symptom onset.
The Fimbrin TvFim1, an immunogenic protein involved in male trichomoniasis.
Exp Parasitol
January 2025
Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México (UACM), San Lorenzo # 290, Col. Del Valle, 03100, México D.F, Mexico. Electronic address:
An active immunoproteome of Trichomonas vaginalis was obtained by 2D-Western blotting (2D-WB). Subsequent proteoform identification by mass spectrometry (MS) showed differential expression and specific immunoreactions of multiple proteins mediated by the presence of Zn. A total of 25 proteoforms were immunologically reactive, generally under Zn conditions, and MS analysis revealed that the fimbrin (plastin) of T.
View Article and Find Full Text PDFEffectiveness and Safety of Mechanical Thrombectomy in Large-Vessel-Occlusion Mild Stroke: Insights from the ASSIST Registry.
AJNR Am J Neuroradiol
December 2024
From the Department of Department of Neuroradiology, University Hospital Heidelberg (S.H.; D. F. V.; M. A. M.); Neuroradiology, Hospital Son Espases, Mallorca, Spain (S.M.); Interventional Neurology, McLaren Regional Medical Center, Flint, Michigan, USA (B.N.); Interventional Neurology, McLaren Regional Medical Center, Macomb, Michigan, USA (B.N.); Neurosurgery, Medical University of South Carolina, Charleston, SC, USA (A.S.); Radiology and Neuroradiology, Klinikum Vest Recklinghausen, Recklinghausen, Germany (C.L.); Interventional Neuroradiology/Endovascular Neurosurgery, Hospital Clínico Universitario de Valladolid, Valladolid, Spain (M.M.G.); Interventional Neuroradiology, Rhode Island Hospital, Providence, Rhode Island, USA (R.M.T.); Vascular and Interventional Radiology, Ghent University Hospital, Ghent, Belgium (L.D.); Radiology, Hospital Universitario Central de Asturias-HUCA, Oviedo, Spain (P.V.); Neuroscience Department, Bon Secours Mercy Health St. Vincent Medical Center, Toledo, Ohio, USA (O.O.Z); Stryker Neurovascular, Fremont, California, USA (P.J.); Neuroradiology Unit, Radiology Department, University Hospital "G. Martino" Messina, Messina, Italy (S.L.V., A.T.); Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA (D.S.L.); Wellstar Medical Group, Neurosurgery, WellStar Health System, Marietta, Georgia, USA (R.G.).
Background And Purpose: Mechanical thrombectomy (MT) is effective for acute ischemic stroke, yet its indication in mild stroke remains unclear. This study evaluates MT's effectiveness and safety in low NIHSS patients and assesses different MT strategies' impact on procedural success and clinical outcomes.
Materials And Methods: Data from the ASSIST Registry were analyzed, categorizing patients with large vessel occlusion of the anterior circulation into mild (NIHSS≤5) and moderate-severe (NIHSS>5) stroke groups.
Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real-World Study.
Neurol Neuroimmunol Neuroinflamm
January 2025
From the Department of Neurology with Experimental Neurology (F.S., S.L., M.S., M.H., P.D., L.M.G., S.H., A.M.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin; Neuroscience Clinical Research Center (F.S., S.L., M.S., M.H., P.D., L.M.G., S.H., A.M.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin; Department of Neurology with Institute of Translational Neurology (C.D.F.S., M.B., C.W.K., L.K., H.W., J.D.L.), University Hospital Münster; Institute of Biometry and Clinical Epidemiology (A.A.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin; Center for Stroke Research Berlin (A.A., M.S., A.M.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Germany; Department of Immunology (K.L.), Hellenic Pasteur Institute; and 2nd Neurology Department (J.T.), School of Medicine, "Attikon" University Hospital, National and Kapodistrian University of Athens, Greece.
Background And Objectives: Biologics that target pathogenic antibodies (Abs) and their effector functions such as the complement inhibitor ravulizumab and the neonatal Fc receptor agonist efgartigimod have recently been approved for the treatment of acetylcholine receptor (AChR)-Ab-positive myasthenia gravis (MG), but comparative studies are lacking.
Methods: In a prospective, exploratory real-world study, we assessed clinical efficacy, safety, and biological effects of ravulizumab and efgartigimod treatment initiation. Myasthenia Gravis-Activities of Daily Living and Quantitative Myasthenia Gravis scores were used as clinical endpoints.
Prolonged Venous Transit on Perfusion Imaging is Associated with Longer Lengths of Stay in Acute Large Vessel Occlusions.
AJNR Am J Neuroradiol
November 2024
From the Department of Radiology (M.K.), Cooper Medical School of Rowan University, Camden, NJ, USA; Department of Radiology (J.Y.M., H.A.S., M.S., H.L., V.S.Y), Department of Neurosurgery (R.X.), and Department of Neurology (V.C.U., E.B.M., R.L., M.B., R.H.L, A.E.H), Johns Hopkins Hospital, Baltimore, MD, USA; Department of Radiology (D.A.L.), West Virginia University Medicine, Morgantown, WV, USA; Department of Neuroradiology (A.A.D.), Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA; Department of Radiology (A.G.), Universite Libre De Bruxelles Hospital, Erasme, Belgium; Department of Radiology (J.J.H., B.P.), Department of Neurology (G.W.A.), Stanford University School of Medicine, Stanford, CA, USA; Department of Radiology (D.W.), Brown University/Rhode Island Hospital, Providence, RI, USA; Department of Radiology (T.D.F.), University Medical Center Munster, Munster, Germany; Department of Radiology (V.V.), Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Department of Radiology (A.S.), Department of Neurology (Y.A.), University of Cincinnati, Cincinnati, OH, USA; Department of Radiology and Biomedical Imaging (K.N.), University of California San Francisco, San Francisco, CA, USA.
Background And Purpose: Prolonged venous transit (PVT+) is a marker of venous outflow; it is defined as the presence or absence of time-to-maximum ≥10 seconds timing in either the superior sagittal sinus or torcula. This novel perfusion imaging-based metric has been associated with higher odds of mortality and lower odds of functional recovery. This study aims to assess the relationship between PVT on admission perfusion imaging and length of hospital stay in large vessel occlusion strokes successfully reperfused with mechanical thrombectomy.
View Article and Find Full Text PDFAggressive Lymphoma after CD19 CAR T-Cell Therapy.
N Engl J Med
October 2024
From the Department of Hematology, Oncology and Clinical Immunology (G.K., B.-N.B., P.-M.B., N.L., A.R., M. Seifert, C.S., U.G., R.-P.C., K.N., P.J., T.U., S.D.), the Institute of Pathology (M. Seidel, I.E.), the Institute for Transplantation Diagnostics and Cellular Therapy (J.C.F., J.M.R.), the Departments of Nuclear Medicine (F.G.), Rheumatology (J.H.W.D.), and Neurology (S.G.M.), and the Hiller Research Center (J.H.W.D.), University Hospital Düsseldorf, the Center for Integrated Oncology, Aachen-Bonn-Cologne-Düsseldorf (G.K., B.-N.B., P.-M.B., N.L., A.R., M. Seifert, C.S., U.G., R.-P.C., K.N., P.J., T.U., S.D.), and the Department of Diagnostic and Interventional Radiology, University Düsseldorf (G.A.), Düsseldorf, Medical Department II, Hematology and Oncology (M.B., H.T.), and the Department of Pathology (I.I.), University Medical Center Schleswig-Holstein, Kiel, the Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin (L.W., F.D.), Berlin Institute of Health, Charité Universitätsmedizin Berlin (S.Y., S.H.), and Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (S.Y., S.H.), Berlin, the Computational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases Heidelberg (N.P.), the Innovation and Service Unit for Bioinformatics and Precision Medicine (D.H.), German Cancer Research Center, the European Molecular Biology Laboratory, Molecular Medicine Partnership Unit (D.F.), German Cancer Consortium (D.H., S.H., F.D.), the Pattern Recognition and Digital Medicine Group, Heidelberg Institute for Stem Cell Technology and Experimental Medicine (D.H.), the Medical Faculty of Heidelberg (J.L.) and the Department of Medicine V (S.D.), Heidelberg University, German Cancer Consortium, partner site Berlin, and German Cancer Research Center (S.H., F.D.), Heidelberg, the Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen (R.K.), and the Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen (M.J.) - all in Germany; and Biomedical Research, Novartis (S.L., P.U.), and Novartis Pharma (H.D.M., H.J.M., J.G.) - both in Basel, Switzerland.
The development of a fatal, clonal, autonomously proliferating CD4-CD8- chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment with tisagenlecleucel for relapsed primary central nervous system lymphoma. The PTCL had a clonal T-cell receptor rearrangement, which was already detectable in the apheresis product for CAR T-cell manufacturing and 7 months earlier for autologous transplantation. Somatic and mutations in CD34+ stem cells and their progeny were detected in the PTCL, in the apheresis specimen that was obtained for CAR T-cell production, and in the autotransplant.
View Article and Find Full Text PDFBeyond the Procedure: The Hidden Crisis of Moral Injury in Interventional Radiology.
Acad Radiol
November 2024
Department of Diagnostic Imaging, Fundación Santa Fe de Bogotá University Hospital, Bogotá D.C., Colombia (J.N.D.N., G.A.M.R., D.F.T.C., A.D.). Electronic address:
Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma.
N Engl J Med
November 2024
From the Department of Neurosurgery, Stony Brook Medicine, Stony Brook, NY (D.F.); the Department of Neurosurgery, Swedish Cherry Hill Hospital, Seattle (S.J.M.); the Department of Neurosurgery, Baptist Memorial Hospital, Jacksonville, FL (R.H.); the Department of Neurosurgery, Swedish Medical Center, Englewood, CO (B.A.); the Department of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University Medicine, Morgantown (S.B.); the Department of Radiology, Rhode Island Hospital, Providence (R.A.M.); the Department of Neurosurgery, Santa Barbara Cottage Hospital, Santa Barbara, CA (A.Z.); the Department of Neurosurgery, Thomas Jefferson Hospital, Philadelphia (S.T.); the Department of Radiology, Centre Hospitalier Universitaire (CHU) Côte de Nacre, Caen (C.B.), the Department of Radiology, CHU Hôpital Bicêtre, Kremlin-Bicêtre (L.S.), and the Department of Radiology, CHU Hôpital Maison Blanche, Reims (L.P.) - all in France; the Department of Neurosurgery, Atlantic Center for Research, Morristown, NJ (R.B.); the Department of Radiology, Massachusetts General Hospital, Boston (J.A.H.); and the Cerebrovascular Program, Vanderbilt University Medical Center, Nashville (M.F.), and the Department of Neurosurgery, University of Tennessee Health Science Center, and the Semmes Murphey Clinic, Memphis (A.S.A.) - all in Tennessee.
Background: Patients receiving standard treatment for chronic subdural hematoma have a high risk of treatment failure. The effect of adjunctive middle meningeal artery embolization on the risk of treatment failure in this population remains unknown.
Methods: We randomly assigned patients with symptomatic chronic subdural hematoma to undergo middle meningeal artery embolization as an adjunct to standard treatment (embolization group) or to receive standard treatment alone (control group).
Effects of Positive Expiratory Pressure Device on Gas Exchange, Atelectasis, Hemodynamics, and Dyspnea in Spontaneously Breathing Critically Ill Subjects.
Respir Care
November 2024
Dipartimento di Scienze Chirurgiche e Diagnostiche Integrate (DISC), Università degli Studi di Genova, Genova, Italy; and Anesthesia and Intensive Care, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Article Synopsis
- - This study examined the EzPAP Positive Airway Pressure System, a noninvasive device designed to help expand the lungs and improve gas exchange, particularly among spontaneously breathing patients with and without tracheostomy.
- - Conducted at a university hospital, the study found that while gas exchange did not significantly change in most patients after PEP, those with tracheostomy showed temporary improvement immediately after treatment, although it did not hold after two hours.
- - Ultimately, the study concluded that while lung expansion improved radiological scores within a week, the PEP therapy did not significantly alleviate respiratory distress in the subjects.
Background: The EXCELLENT registry aimed to evaluate the effectiveness of the EMBOTRAP Revascularization Device in an all-comer population in a real-world setting, with a focus on the composition of retrieved clots.
Methods: EXCELLENT is a prospective, global registry of patients with acute ischemic stroke treated with EMBOTRAP as the first-line mechanical thrombectomy device conducted at 34 sites (25 sites contributing clot) from September 2018 to March 2021, utilizing core imaging and central histology laboratories blinded to clinical data, independent 90-day modified Rankin Scale assessment and Clinical Events Committee.
Results: After screening 3799 patients, a total of 997 subjects (mean age, 70.
The QIBA Profile for Diffusion-Weighted MRI: Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker.
Radiology
October 2024
From the Center for Research and Innovation, American College of Radiology, 50 S 16th St, Philadelphia, PA 19102 (M.A.B.); Department of Radiology, University of Michigan, Ann Arbor, Mich (D.M., T.L.C.); Department of Radiology, University of Washington, Seattle, Wash (S.P.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Departments of Medical Physics and Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (A.S.D.); The Institute of Cancer Research, London, UK (J.M.W., N.M.d.S.); The Royal Marsden NHS Foundation Trust, London, UK (J.M.W., N.M.d.S.); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex (C.D.F.); CaliberMRI, Boulder, Colo (K.M.); Department of Radiology, University of Alabama at Birmingham, Birmingham, Ala (V.M.); Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, Calif (M.O., L.J.W.); Aim Medical Imaging, Vancouver, Canada (R.A.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (T.A.); and Department of Radiology, Weill Cornell Medical College, New York, NY (D.J.M.).
Article Synopsis
- The Apparent Diffusion Coefficient (ADC) measures how water moves in tissues, helping doctors see changes caused by diseases or treatments.
- The QIBA has made progress on using ADC measurements in different body parts like the brain, liver, prostate, and breast, by creating guidelines for their use.
- The report explains the right amounts of change in ADC values that indicate real differences in tissue, helping doctors track patients’ health more accurately.
Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry.
Circulation
October 2024
Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy (N.M., C.F., I.O.).
Article Synopsis
- Septal reduction therapy (SRT) significantly improves symptoms for patients with obstructive hypertrophic cardiomyopathy (HCM), but its long-term results and predictors of adverse outcomes still need more study.* -
- An analysis of data from the SHARE registry revealed that among 1,832 patients who underwent SRT, the 30-day mortality rate was low at 0.4%, and after approximately 6.8 years, rates for HCM-related death, heart failure, and ventricular arrhythmias were relatively low.* -
- Key findings included that older age at SRT increases risks for HCM death and heart failure outcomes, while female patients showed higher susceptibility to heart failure complications post-treatment.*
Prevalence and Risk Factors for Secondary Hypertension in Young Adults.
Hypertension
November 2024
Hypertension Unit (J.-B.d.F., M.G., S.C., G.B., N.G., A.L., C.M., A.-M.M., J.R., N.P.-V., M.A., L.A.), Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France.
Article Synopsis
- - The study focused on understanding how common secondary hypertension (2HTN) is in young adults aged 18 to 40, finding that nearly 30% of patients had 2HTN.
- - The most common causes of 2HTN were identified as primary aldosteronism, renovascular hypertension, and kidney diseases, with certain factors like being female and having a lower BMI linked to a higher prevalence.
- - Based on their findings, the researchers recommend that all young adults with hypertension should be screened for secondary causes, as there is a significant risk present regardless of age or blood pressure levels.
CADA-PRO: A Patient Questionnaire Measuring Key Cognitive, Motor, Emotional, and Behavioral Outcomes in CADASIL.
Stroke
October 2024
ARAMIS, Sorbonne Université, Paris Brain Institute (ICM Institut du Cerveau), Institut national de recherche en sciences et technologies du numérique (INRIA), Institut national de la santé et de la recherche médicale (INSERM), Assistance Publique - Hôpitaux de Paris, Groupe Hospitalier Sorbonne Université, Paris, France (C.D.F., J.A., S.T.d.M.).
Background: Cerebral small vessel disease (cSVD) of ischemic type, either sporadic or genetic, as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), can impact the quality of daily life on various cognitive, motor, emotional, or behavioral aspects. No instrument has been developed to measure these outcomes from the patient's perspective. We thus aimed to develop and validate a patient-reported questionnaire.
View Article and Find Full Text PDFInvasive Treatment Strategy for Older Patients with Myocardial Infarction.
N Engl J Med
November 2024
From the Translational and Clinical Research Institute, Faculty of Medical Sciences (V.K.), the Population Health Sciences Institute (H.M., M.D.T.), and the Newcastle Clinical Trials Unit (C.S., M. Bardgett, P.W., M.D.T., J.P.), Newcastle University, and the Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust (V.K., J.A.H., I.U.H.), Newcastle upon Tyne; Northumbria Healthcare NHS Foundation Trust, Cramlington (C.R., D.P.R.); the Faculty of Health Sciences and Wellbeing, School of Medicine, University of Sunderland Medical School, Sunderland (D.P.R.); North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees (J. Carter, J.Q.); Chesterfield Royal Hospital, Chesterfield (J. Cooke); South Tees NHS Foundation Trust, Middlesbrough (D.A.); County Darlington and Durham NHS Foundation Trust, Darlington (J. Murphy); Royal Derby Hospital, Derby (D.K.); University Hospital Ayr, Ayr (J. McGowan); Leeds Teaching Hospital NHS Trust, Leeds (M.V.); Torbay and South Devon NHS Foundation Trust, Torquay (D.F.); Manchester University NHS Foundation Trust, Manchester (H.C.); Epsom and St. Helier University Hospitals, Epsom (S.M.); Ninewells Hospital, Dundee (J.I.); Bradford Royal Infirmary, Bradford (S.L.); Blackpool Victoria Hospital, Blackpool (G.G.); United Lincolnshire Hospitals NHS Trust, Lincoln (K.L.); Wrightington Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan (A.S.); North Bristol NHS Trust, Bristol (A.G.D.); University Hospital of Leicester NHS Trust, Leicester (S.H.); Barts Health NHS Trust (M. Belder) and London School of Hygiene and Tropical Medicine (S.J.P.), London; the Centre for Cardiovascular Science, University of Edinburgh, Edinburgh (M.D., D.E.N., K.A.A.F.); Norwich Medical School, University of East Anglia, Norwich (M.F.); and Sheffield Teaching Hospital, Sheffield (R.F.S.) - all in the United Kingdom.
Background: Whether a conservative strategy of medical therapy alone or a strategy of medical therapy plus invasive treatment is more beneficial in older adults with non-ST-segment elevation myocardial infarction (NSTEMI) remains unclear.
Methods: We conducted a prospective, multicenter, randomized trial involving patients 75 years of age or older with NSTEMI at 48 sites in the United Kingdom. The patients were assigned in a 1:1 ratio to a conservative strategy of the best available medical therapy or an invasive strategy of coronary angiography and revascularization plus the best available medical therapy.
Does the Visual Field Improve After Initiation of Intraocular Pressure Lowering in the United Kingdom Glaucoma Treatment Study?
Am J Ophthalmol
January 2025
From the Department of Optometry and Visual Sciences (P.F.R., S.R.K., G.O., D.P.C.), School of Health and Psychological Sciences, City, University of London, London, United Kingdom. Electronic address:
Purpose: Evidence to support the hypothesis that visual field (VF) status can improve after initiation of intraocular pressure (IOP) reducing treatment is controversial. We take advantage of participant eligibility data from the United Kingdom Glaucoma Treatment Study (UKGTS) to test this hypothesis in newly diagnosed glaucomatous patients randomized to IOP-lowering therapy or placebo.
Design: Multicentre, randomized, triple-masked, placebo-controlled trial.
Longitudinal Changes of Clinical, Imaging, and Fluid Biomarkers in Preataxic and Early Ataxic Spinocerebellar Ataxia Type 2 and 7 Carriers.
Neurology
September 2024
From the Sorbonne Université (G.C., C.D.-F., E.P., S.S., L.D., P.C., R.K., R.H., H.H., J.-C.L., M.-L.W., P.P., A.B., S.T.d.M., A.D.), Paris Brain Institute, Inserm, CNRS, INRIA, APHP; CATI (C.F., M.C., J.-F.M.), US52-UAR2031, CEA, Paris Brain Institute, Sorbonne Université, CNRS, INSERM, APHP; Sorbonne Université (M.N., I.A.), Inserm, CNRS, Institut de la Vision; Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (M.N., I.A.), National Rare Disease Center REFERET and INSERM-DGOS CIC 1423; Sorbonne Université (P.G.), Inserm, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique; Sorbonne Université (K.D.), Inserm, Centre d'Immunologie et des Maladies Infectieuses-Paris (CIMI-Paris), France; P3lab (P.D.), Louvain-la-Neuve, Belgique; Clinical Metabolomic Department (A.L.), Assistance Publique-Hôpitaux de Paris, Saint Antoine Hospital, Saint-Antoine Research Center, Sorbonne University, France; Ionis Pharmaceuticals (R.L.), Carlsbad, CA; and Service de Neurophysiologie (B.G.), University Hospital Pitié-Salpêtrière, Paris, France.
Article Synopsis
- - The study investigated changes in biological, clinical, and imaging markers in carriers of spinocerebellar ataxia (SCA) types 2 and 7 over one year, focusing on MRI and neurofilament light chain (NfL) levels.
- - It included assessments of neurological function, quality of life, and brain imaging among 15 SCA2 carriers, 15 SCA7 carriers, and 10 control subjects, while noting differences in SARA scores and brain volume from baseline measurements.
- - Results indicated significant brain volume loss and worsening motor function in SCA2 carriers, an increase in SARA scores and thinning of retinal layers in SCA7, highlighting the progressive nature of these at
Multicenter Experience with the Pipeline Flex and Vantage with Shield Technology for Intracranial Aneurysm Treatment.
AJNR Am J Neuroradiol
October 2024
From the Department of Radiology and Neuroradiology (L.G., D.Z., L.P., J.K., M.S., C.K.), University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany.
Background And Purpose: The Pipeline Embolization Device is a safe and effective treatment option for intracranial aneurysms. The newer Pipeline generations have received structural refinements and a surface modification to improve deliverability, procedural safety, and angiographic outcomes. This multicenter study evaluated the clinical safety and efficacy of the 2 surface-modified Pipeline iterations, Pipeline Vantage and Pipeline Flex with Shield Technology (PFS).
View Article and Find Full Text PDFSacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial.
JACC Heart Fail
August 2024
Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address:
Chronic Chagas cardiomyopathy (CCC) has unique pathogenic and clinical features with worse prognosis than other causes of heart failure (HF), despite the fact that patients with CCC are often younger and have fewer comorbidities. Patients with CCC were not adequately represented in any of the landmark HF studies that support current treatment guidelines. PARACHUTE-HF (Prevention And Reduction of Adverse outcomes in Chagasic Heart failUre Trial Evaluation) is an active-controlled, randomized, phase IV trial designed to evaluate the effect of sacubitril/valsartan 200 mg twice daily vs enalapril 10 mg twice daily added to standard of care treatment for HF.
View Article and Find Full Text PDFAssessment of Thrombectomy versus Combined Thrombolysis and Thrombectomy in Patients with Acute Ischemic Stroke and Medium Vessel Occlusion.
Radiology
August 2024
From the Neuroendovascular Program, Massachusetts General Hospital & Brigham and Women's Hospital, Harvard University, Boston, Mass (A.A.D., R.W.R., C.J.S., J.D.R., A.B.P.); Departments of Medical Imaging and Neurosurgery, Neurovascular Centre, St. Michael's Hospital, Toronto, ON, Canada M5B 1W8 (A.A.D., N.M.C., T.R.M., V.M.P.); Departments of Neurologic Surgery & Radiology, Mayo Clinic, Rochester, Minn (S.G., H.K., R.K.); Cooper Neurologic Institute, Cooper University Hospital, Cooper Medical School of Rowen University, Camden, NJ (J.E.S., H.S., J.K., A.J.T., A.G.); Departments of Radiology & Neurology, Boston Medical Center, Boston, Mass (M.A., P. Klein, T.N.N.); Department of Interventional Neuroradiology, Stanford Medical Center, Palo Alto, Calif (J.J.H.); Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pa (K.E.N., A.A., S.I.T., P.J.); Department of Neurosurgery and Interventional Neuroradiology, Louisiana State University, Shreveport, La (H.A.S., B.M., N.A., H.H.C.S.); Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (L.M., J.F. T.D.F.); Department of Neurology, Hôpital Civil Marie Curie, Charleroi, Belgium (A.D., F.B.); Department of Neuroradiology, University Hospital of Limoges, Université de Limoges, Limoges, France (G.F., A.R., S. Saleme, C.M.); Department of Radiology, Division of Neurointerventional Radiology, University of Massachusetts Medical Center, Worcester, Mass (A.L.K., A.S.P.); Department of Neuroradiology, Sana Kliniken, Lübeck GmbH, Lübeck, Germany (C.D.); Department of Neurosurgery, University of Texas Medical Branch, Galveston, Tex (P.T.K., M.C.); Department of Interventional Neuroradiology, Bordeaux University Hospital, Bordeaux, France (G.M., J.B., X.B.); Department of Neurology, Bordeaux University Hospital, Bordeaux, France (I.S.); Department of Neurology, University of Massachusetts Chan Medical School, Worcester, Mass (S.N., N.H.); Department of Psychiatry, University of Massachusetts Chan Medical School, Worcester, Mass (N.H.); Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass (N.H.); Department of Neurosurgery, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan (T.O., S.D.); Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (L.L.L.Y., B.Y.Q.T.); Department of Medicine, Division of Neurology, National University Hospital, Singapore (B.Y.Q.T.); Department of Neurology, UTHealth McGovern Medical School, Houston, Tex (J.C.M.G., S.S.M.); Interventistica Neurovascolare, Ospedale Careggi di Firenze, Florence, Italy (S. Sheth, L.R., C.C.); Department of Neurologic Surgery, Division of Stroke and Endovascular Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, Calif (A.M.); Department of Endovascular Neurosurgery and Neuroradiology, Rutgers University New Jersey Medical School in Newark, Newark, NJ (P. Khandelwal); Department of Neurosurgery, Westchester Medical Center at New York Medical College, Valhalla, NY (A.B.); Department of Neuroradiology, Pitié-Salpêtrière Hospital, GRC BioFast, Sorbonne University, Paris, France (F.C., M.E., K.P.); Neurology Department, Faculty of Medicine, Tanta University, Egypt (M.E.); UOSA Neuroradiologia Interventistica, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy (I.V., A.P., A.M.A.); Department of Diagnostic and Interventional Neuroradiology, Centro Hospitalar Universitário do Porto, Porto, Portugal (J.P.F.); Department of Neurology, Centro Hospitalar Universitário do Porto, Porto, Portugal (R.V.); Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, Calif (M.Q.C., N.R.G.); Department of Vascular and Interventional Neuroradiology, Universitätsklinikum Heidelberg, Heidelberg, Germany (M.A.M., J.J., C.W.); Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France (V.C., R.A.R.); Department of Neurology, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France (A.t.S.); Department of Radiology, Division of Neuroradiology, Johns Hopkins Medical Center, Baltimore, Md (V.Y.); Department of Neurology, University of Cincinnati Medical Center, Cincinnati, Ohio (P.H., L.M.C., Y.A.); Department of Interventional Neuroradiology, Nancy University Hospital, Nancy, France (B.G.); INSERM U1254, IADI, Université de Lorraine, Nancy, France (B.G.); Department of Radiology, Section of Interventional Neuroradiology, University Medical Center Münster, Münster, Germany (C.P.S.); Departments of Neurology & Neurosurgery, Christian Doppler Clinic, Paracelsus Medical University, Salzburg, Austria (C.H., M.K.O., C.J.G.); Department of Neurology, Sin-Lau Hospital, Tainan, Taiwan (C.Y.H.); UCLA Stroke Center and Department of Neurology Department, University of California Los Angeles, Los Angeles, Calif (D.S.L.); Department of Medicine, Division of Neurology, The Ottawa Hospital, Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada (I.T., R.F.); Department of Diagnostic and Interventional Neuroradiology, Erasme University Hospital, Brussels, Belgium (B.L.).
Article Synopsis
- * Data from 670 patients revealed that while IVT may improve some outcomes, such as higher chances of achieving a modified Rankin Scale score of 0-2 in univariable analysis, this benefit was not consistently observed in more rigorous multivariable analyses.
- * Overall, the findings suggest that adjunctive IVT may not significantly enhance clinical outcomes or safety compared to MT alone for this patient population.
Proximal Interruption of the Pulmonary Artery.
Radiology
July 2024
From the Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Avenida Doutor Enéas Carvalho de Aguiar, 44-Cerqueira César, São Paulo-SP, 05403-900, Brazil (L.d.P.G.d.F., C.H.N.); Hospital Sírio-Libanês, São Paulo, Brazil (L.d.P.G.d.F., C.H.N.); and Alliança Saúde, São Paulo, Brazil (L.d.P.G.d.F.).
Interhospital Transfer for Endovascular Stroke Treatment in Canada: Results From the OPTIMISE Registry.
Stroke
August 2024
Division of Neurology, Department of Medicine, The Ottawa Hospital, ON, Canada (R.F., G.S.).
Background: Interhospital transfer for patients with stroke due to large vessel occlusion for endovascular thrombectomy (EVT) has been associated with treatment delays.
Methods: We analyzed data from Optimizing Patient Treatment in Major Ischemic Stroke With EVT, a quality improvement registry to support EVT implementation in Canada. We assessed for unadjusted differences in baseline characteristics, time metrics, and procedural outcomes between patients with large vessel occlusion transferred for EVT and those directly admitted to an EVT-capable center.
Association of Body Mass Index and Parkinson Disease: A Bidirectional Mendelian Randomization Study.
Neurology
August 2024
From the Université Paris-Saclay (C.D., P.-E.S., B.P., A.E.), UVSQ, Inserm, Gustave Roussy, CESP, Villejuif, France; Centre for Genetic Epidemiology (A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, and Department for Neurodegenerative Diseases (C.S., K.B., T.G.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., K.B., T.G.), Tubingen; Center for Human Genetics (S.G.), Universitatsklinikum Giessen und Marburg, Germany; Department of Public Health (P.-C.L.), National Cheng Kung University, Tainan, Taiwan; Translational Neuroscience (P.M., D.B., R.K.), Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Molecular Genetics Section (A.B.S., D.H., C.E.), Laboratory of Neurogenetics, and Center for Alzheimer's and Related Dementias (A.B.S.), NIA, NIH, Bethesda, MD; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Nathan, Australia; Department of Neurology (A.A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Tanz Centre for Research in Neurodegenerative Diseases (E.A.R., A.E.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.E.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.E.L.), University of Toronto; Krembil Brain Institute (A.E.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic (P.T.), Tartu University Hospital, Estonia; Department of Neurologie (S.L., A.B., J.-C.C.), Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Sorbonne Université; Assistance Publique Hôpitaux de Paris (J.-C.C.), Department of Neurology, CIC Neurosciences; Univ. Lille (M.-C.C.-H., E.M.), Inserm, CHU Lille, UMR-S 1172-LilNCog-Centre de Recherche Lille Neurosciences & Cognition, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Greece; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia; 1st Department of Neurology (L. Stefanis, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens; Center of Clinical Research, Experimental Surgery and Translational Research (L. Stefanis), Biomedical Research Foundation of the Academy of Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital, Rome; Department of Clinical and Molecular Medicine (S.P.), University of Rome; Department of Biomedical Sciences (L. Straniero), Humanitas University, Milan; Parkinson Institute (A.L.Z.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano; Parkinson Institute (G.P.), Fontazione Grigioni-Via Zuretti, Milan; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Monza; Department of Medicine and Surgery and Milan Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Milano; Institute for Biomedical Research and Innovation (G.A.), National Research Council, Cosenza; Institute of Neurology (A.Q.), Magna Graecia University; Institute of Molecular Bioimaging and Physiology National Research Council (M.G.), Catanzaro, Italy; Department of Integrative Physiology and Bio-Nano Medicine (H.M., A.N.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Neurology (P.K., R.K.), Centre Hospitalier de Luxembourg; Department of Neurology (B.P.C.V.D.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Radboud University Medical Centre, the Netherlands; Department of Neurology (M.T., L.P.), Oslo University Hospital, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit (E.T.), Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) (E.T.); Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.-F.), Terrassa; Movement Disorders Unit (P.P., M.D.-F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), and Department of Neuroscience (C.R., A.C.B.), Karolinska Institutet, Stockholm; Department of Clinical Sciences Lund (A.P., C.H.), Neurology, Skåne University Hospital, Lund University, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine (K.E.M.), Health and Life Sciences, Queens University, Belfast; Department of Clinical and Movement Neurosciences (M.M.T.), UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology (D.K., L.F.B.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.); German Center for Neurodegenerative Diseases (DZNE) (L.F.B.), Munich, Germany; Department of Neurology (M.F.), McKnight Brain Institute, University of Florida, Gainesville; Parkinson's Research Clinic (R.K.), Centre Hospitalier de Luxembourg; and Transversal Translational Medicine (R.K.), Luxembourg Institute of Health (LIH), Strassen.
Article Synopsis
- The study investigates the relationship between body mass index (BMI) and Parkinson's disease (PD) using a method called Mendelian randomization to determine if higher genetically predicted BMI is linked to a lower incidence of PD.
- Researchers analyzed genetic data from large groups of individuals, including over 800,000 for BMI and nearly 29,000 for PD, focusing on factors like age, disease duration, and gender to examine the associations.
- Results indicated an inverse relationship between genetically predicted BMI and PD, particularly among younger participants and women, suggesting that lower BMI may be associated with a higher risk of developing Parkinson's disease.
A narrative review of inherited arrhythmogenic syndromes in young population: role of genetic diagnosis in exercise recommendations.
BMJ Open Sport Exerc Med
July 2024
Medical Science Department, School of Medicine, Universitat de Girona, Girona, Spain.
Article Synopsis
- - Sudden cardiac death, especially among young people, is a rare and tragic event often triggered during or right after exercise, with inherited arrhythmogenic syndromes being a primary cause.
- - These genetic conditions can lead to dangerous heart rhythms, and sometimes, the first sign of a problem is a sudden cardiac event, emphasizing the importance of assessing family members for genetic risks.
- - Early detection and individualized preventive measures are essential to mitigate risks, and while exercise is generally beneficial, specific guidelines should be tailored to each patient's genetic background and health status.